| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5010b8729898cc3f8a9f2d82ee81ddf1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e5351c62aee4203f2be2944f21a6def2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c0a9ebe1a2ee79a1782bd9c4a1f7dfff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3f005768f3b3abee4e57f55916ac8003
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a9fa854469018cf904c97ea1ac6c946c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-14 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C311-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C311-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 |
| filingDate |
2011-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e204bd597d09175ed492ff40288d4648
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c69c8b167e74d4d38fc609a3a30dd914
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c990bc0feb704a872d923ebe0165c36e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_acabc4271bba0a2b89a485b39c48725b |
| publicationDate |
2012-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2012124858-A1 |
| titleOfInvention |
Pharmaceutical composition with enhanced efficacy for inhibiting angiogenesis |
| abstract |
The present invention relates to a pharmaceutical composition for inhibiting angiogenesis and a novel sulfonyl amide derivative compound which can be useful for the prevention or treatment of angiogenesis-related diseases or disorders. Since the compound used as an active ingredient in the pharmaceutical composition of the invention is specifically bound to UQCRB and inhibits biological functions thereof, apoptosis is not induced and angiogenic responses are inhibited. Therefore, the compound used as an active ingredient in the pharmaceutical composition of the invention can be useful as an effective and safe angiogenesis inhibitory agent. |
| priorityDate |
2011-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |